You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

CARDIOVASCULAR DISEASES UNDER THE ACTION OF OCCUPATIONAL FACTORS

2(22) 2010

DOI xxxxxxxx

Basanets A. V., Andruschenko T. A.

CARDIOVASCULAR DISEASES UNDER THE ACTION OF OCCUPATIONAL FACTORS

SI «Institute for occupational health of AMS of Ukraine», Kyiv

Full article (PDF), UKR

The problem of cardiovascular diseases of different contingents of the working population is discussed in the article. Occupational factors of the modern production, which can occur as etiological agents of CVD, pathogenesis, peculiarities of clinical picture and the course of cardiovascular diseases under the influence of the working environment have been defined. Actual problems, concerning developing preventive measures for cardiovascular disease and their complications, which can result in disability and reduction of life duration of the working population have been elucidated.

Key words: cardiovascular diseases, professional factors, pathogenesis, clinical picture, prevention

References

  1. Kundiev Yu. I., Nahorna A.M. (2007), Profesiyne zdorov'ya v Ukrayini, epidemiolohichnyy analiz [Occupational health in Ukraine. Epidemiological analysis], Avicenna, Kiev, Ukraine.
  2. Kannel W. B. Epidemiology and prevention of cardiac failure: Framingham Study insights / W. B. Kannel / / Europ. Heart J.- 1987.- V. 8, Suppl. F.- P. 23-26.
  3. Baranov V. S. Geny predraspolozhennosti i geneticheskiy pasport / V. S. Baranov, M. V. Aseyev, V. Ye. Baranova // Priroda.- 1999.- No 3.- S. 13-17.
  4. Raptova smert, reanimatsiya i intensyvna terapiya / Volnyy I. F., Pasternak.H. I., Pyeshkov YU. V., Tkacheva M. YU. // Ekstrena medychna dopomoha na do hospitalʹnomu etapi.- Luhansk.- 2006.- S. 29-34.
  5. Voronkov L. H. Khronichna sertseva nedostatnist: Praktychnyy posibnyk / L. H. Voronkov.- K.: Chetverta khvylya, 2004.- 198 s.
  6. Mazur N. A. Rekomendatsiyi po raptoviy smerti / Rosiyskyy Konhres kardiolohiv. Dopovid (prezentatsiya natsionalnykh rekomendatsiy VNOK) / N. A. Mazur.- Moskva, 2003.- S. 190.
  7. Kompleksna profilaktyka raptovoyi smerti, infarktu miokarda, mozkovoho insultu ta yikh naslidkiv u hirnykiv vuhilnykh shakht, metodychni rekomendatsiyi / [Valutsyna V. M., Cherkesov V. V., Pered eriy H. S. ta in.].- Kyiv, 2008.- S. 31.
  8. Okorokov A. N. Raptova sertseva smert (pervynna zupynka sertsya) / A. N. Okorokov // Diahnostyka khvorob vnutrishnikh orhaniv. Diahnostyka khvorob sertsya i sudyn.- Moskva: Medychna literatura.- 2002.- T. 6.- S. 414-423.
  9. Kryvohlaz B. A. Zakhvoryuvannya sertsevo-sudynnoyi systemy, yikh profilaktyka i likuvannya (v dopomohu lektoram) / B. A. Kryvohlaz.- Kyiv, 1957.- S. 22.
  10. Hirnychyy Zakon Ukrayiny (st. 40) // Postanova Kabinetu Ministriv vid 18 lyutoho 2004 r. No 186 “Pro vnesennya zmin po Prohrami pidvyshchennya bezpeky pratsi na vuhilnykh shakhtakh” (p. 99).
  11. Korzh YE. V. Patolohiya lehen i sertsya u shakhtariv: Monohrafiya / Ye. V. Korzh, V. V., Mukhin.- Donetsk: Kashtan, 2004.- S. 164.
  12. Kobets H P. Ishemichna khvoroba sertsya u hirnychykh pratsivnykiv / H. P. Kobets, V. V. Cherkesov, R. A. Kopytina.- Kyiv: Zdorov'ya.- 1995.- S. 161.
  13. Trakhtenberg I.M., Babayan A.S., Kandaryan K.A. (1992), Khimichni faktory vyrobnychoho seredovyshcha i sertsevo-sudynna systema [Chemical factors of the work environment and cardio-vascular system], Aiastan, Yerevan, Armenia.
  14. Otsinka ta modyfikatsiya ryzyku sertsevo-sudynnykh uskladnen u khvorykh z arterialnoyu hipertenziyeyu (metodychni rekomendatsiyi) / [Zharinov O. Y., Bobrova O. V., Vyeryezhnikova H. P. ta in.].- Kyiv.- 2009.- S. 18.
  15. Dzyak G. V. Sutochnoye monitorirovaniye arterial'nogo davleniya / G V. Dzyak, T. V. Kolesnik, YU. N. Pogoretskiy.- Dnepropetrovsk, 2005.- S. 200.
  16. Rekomendatsiyi Ukrayinskoho tovarystva kardiolohiv z profilaktyky ta likuvannya arterialnoyi hipertenziyi.- K., 2008.- S. 76.
  17. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European society of Cardiology. 2007 Guidelines for the management of arterial hypertension // Europ. Heart J.- 2007.- V.28.- P. 1462-1536.
  18. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report // JAMA.- 2003.- V. 289.- P. 3560 -3572.
  19. Boytsov S. A. Desyat' let poiska geneticheskoy osnovy gipertonicheskoy bolezni: trudnosti i perspektivy / S. A. Boytsov // Genetika.- 2002.- T. 8, No 5.- S. 56-64
  20. Kliniko-geneticheskiye aspekty gipotenzivnogo otveta i obratnogo razvitiya gipertrofii levogo zheludochka u bol'nykh arterial'noy gipertoniyey / [Moiseyev V. S., Kotovskaya Yu. V., Kobalava ZH. D. i dr.] // Terapevticheskiy arkhiv.- 2002.- No 10.- C. 30-37.
  21. Geneticheskiye markery gipertrofii miokarda levogo zheludochka / [Karpov R. S., Puzyrev K. V., Stepanov V. A. i dr.] // Arterial'naya gipertenziya.- 1999.- T 5.- S. 54.
  22. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANF Study) / [Anderson T. J., Elstein E., Haber H. et al.].- J Am Coll Cardiol. 2000.- No 35.- Р 60-66.
  23. Konchalovskaya N. M. Serdechno-sosudistaya sistema pri deystvii professional'nykh faktorov / N. M. Konchalovskaya.- M.: Meditsina, 1976-S. 256.
  24. K otsenke roli proizvodstvennykh faktorov glubokikh ugol'nykh shakht v razvitii ishemicheskoy bolezni serdtsa u gornorabochikh / [Kobets' G P., Cherkesov V. V., Kopytina R. A. i dr.] // Gigiyena truda i profpatologiya.- M, 1992.- S. 7-9.
  25. Kholopkina N.A., Gorblyanskiy YU. YU. Monitoring faktorov riska vozniknoveniya serdechno-sosudistykh zabolevaniy u shakhtorov, stradayushchikh arterial'noy gipertoniyey / N. A. Kholopkina, YU. YU. Gorblyanskiy // Gigiyena truda i profpatologiya.- M., 2003.- S. 59-61.
  26. Drobyshev V. V., Yefremov A. V., Loseva M. I. i dr. // Terapevticheskiy arkhiv.- 2002.- No 10.- S. 62-65.
  27. Profilaktika, diagnostika i lecheniye pervichnoy arterial'noy gipertenzii v Rossiyskoy Federatsii: Pervyy doklad Nauchnogo obshchestva po izucheniyu arterial'noy gipertonii Vserossiyskogo nauchnogo obshchestva kardiologov i Mezhvedomstvennogo soneta po serdechno-sosudistym zabolevaniyam (DAG Í) // Kardiologiya.- 2000.- No 11.- S. 65-93.
  28. Organov R. G // Vrach.- 2001.- No 7.- S. 3-6.
  29. Kobalava ZH. D., Kotovskaya YU. V. // Arterial'naya gipertoniya v voprosakh i otvetakh.- M., 2002.- S. 35-37.
  30. Epidemiologiya svyazannykh s rabotoy bolezney i neschastnykh sluchav // Doklad ob"yedinennogo komiteta MOT VOZ po prof. gigiyene. Seriya tekhn. doklad., 10-y.- Zheneva, 1991.
  31. Rekomendatsiyi Yevropeyskoho tovarystva z hipertenziyi ta Yevropeyskoho kardiolohichnoho tovarystva z likuvannya arterialnoyi hipertenziyi // Journal of Hyper- tention.- 2003.- V. 21.- P. 1011-1053.
  32. Novyye rekomendatsii po diagnostike i lecheniyu arterial'noy gipertenzii dlya Yevropy i Severnoy Ameriki (kommentariy) / Yu. N. Sirenko (2007) // Medicine Review.- 2008.- No 2 (02).- C. 8-11.
  33. Birkenhager-Essential hypertension / Jan A. Staessen, Jiguang Wang, Giuseppe Bianchi, Willem H // LANCET, 2003.- V. 361.- Р 1629-41.
  34. Novyye predstavleniya o patogeneze khronicheskoy serouglerodnoy intoksikatsii / Kundiev Yu. I., Popov T.A., Krasnyuk Ye.P., Lukhtay V.A. // Vrachebnoye delo.- 1978.- S. 7, 9-11.
  35. Vorob'yev Ye. I. Radiatsionnaya kardiologiya / Ye. I. Vorob'yev.- M.: Atomizdat, 1971.
  36. Uroven' endoteliyzavisimoy vazodilatatsii i aktivnost' angiotenzinprevrashchayushchego fermenta kak kriteriy terapii bol'nykh s myagkoy i umerennoy arterial'noy gipertoniyey / [Yakimenko O. N., Gomazkov O. A., Ektova T. V. i dr.] // Kardiologiya.- 2005.- No 2.- S. 15-19.
  37. Moiseyev V. S. Arterial'naya gipertoniya u lits starshikh vozrastnykh grupp / V. S. Moiseyev, ZH. D. Kobalava.- Moskva: Meditsinskoye informatsionnoye agentstvo, 2002.- S. 80-95.
  38. Vorob'yev Ye. I. Sostoyaniye kletok miokarda krolikov posle lokal'nogo oblucheniya oblasti serdtsa / Vorob'yev Ye. I., Stepanov R P. // Radiobiologiya.- 1973.- No 6.- S. 844-849.
  39. Evans W. E. Pharmacogenomics-Drug Disposition, Drug Targets, and Side Effects / Evans W. E., McLeod H. L. // N.Engl.J. Med.- 2003.- V. 348, No 6.- P 538-546.
  40. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight / [Wang X., Zuckerman B., Pearson C. at al.] // J.A.M.A.- 2002.- V. 287.- Р 195-202.
  41. Karnaukh N. G. Zabolevayemost' i funktsional'noye sostoyaniye serdechno-sosudistoy sistemy u metallurgov / Karnauk N. G, Pavlenko M. Ye. // Sb. Gigiyena truda.- 1978.- Vyp. 14.- S. 28-31.
  42. Gorban' L. N. Vliyaniye usloviy truda na sostoyaniye zdorov'ya i zabolevayemost' rabotayushchikh v svarochnom proizvodstve / Gorban' L. N., Krasnyuk Ye. P., Faktorov I. Ye. // Sb. Gigiyena truda.- 1963.- Vyp. 19.- S. 40-49.
  43. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis. A 3-year follow-up study / [Sander D., Kukla C., Klingelhofer J. et al.] // Circulation.- 2000.- V. 102.- P 1536-1541.
  44. Respiratory disease and cardiovascular morbidity / Koskela R.- S., Mutanen P., Sorsa J.- A., Klockars M. // Occupational and Environmental Medicine.- 2005.- V. 62.- P 650-655.
  45. Villeneuve P. J. Coronary heart disease mortality among Newfoundland fluorspar miners. Department of Preventive Medicine and Biostatistics, University of Toronto, Laboratory Centre for Disease Control, Health Canada / Villeneuve P J., Morrison H. I. // Scandinavian journal of work, environment & health ISSN 0355-3140.1997.- V. 23.- No 3.- P 221-226 (29 ref.).
  46. Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor/ [Sophie Van Linthout, Frank Spillmann, Mario Lorenz et al.] // Hypertension.- 2009.- V. 53.- P. 587-589.
  47. Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology / [Shant Der Sarkissian, Justin L. Grobe, Lihui Yuan et al.] // Hypertension.- 2008.- V. 51.- P 712.
  48. Mohan K. Raizada. Potential of Gene Therapy Strategy for the Treatment of Hypertension / Mohan K. Raizada, Shant Der Sarkissian // Hypertension.- 2006.- V. 47.- P. 6.
  49. Der Sarkissian S., Huentelman M.J., Stewart J., Katovich M.J., Raizada M.K. ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2005:Jul 8.
  50. Pachori A.S., Huentelman M.J., Francis S.C., Gelband C.H., Katovich M.J., Raizada M.K. The future of hypertension therapy: sense, antisense, or nonsense? Hypertension.- 2001.- V. 37.- P. 357-364.
  51. Blakita I. V. Biokhimicheskiye izmeneniya v miokarde pri khronicheskom vozdeystvii etilmerkurkhlorida i khlorofosa / I. V. Blakita // Gig. tr. i prof. zd-ya.- 1986.- No 5.- S. 46-47.
  52. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats / [Zhao C., Wang P., Xiao X. et al.] // Hypertension.- 2003.- V. 42.- P. 1026-1033.
  53. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen / [Tomita N., Morishita R., Higaki J. et al.] // Hypertension.- 1995.- V. 26.- P. 131-136.
  54. Galli S. M. Angiotensin II AT(1A) receptor antisense lowers blood pressure in acute 2-kidney, 1-clip hypertension / Galli S. M., Phillips M. I. // Hypertension.- V. 38,-P. 674-678.
  55. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense / Lyer S. N., Lu D., Katovich M. J., Raizada M.K // Proc Natl Acad Sci U S A.- 1996.- V. 93.- P. 9960 -9965.
  56. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy / [Pachori A. S., Numan M. T., Ferrario C.M. et al.] // Hypertension.- V. 39.- P. 969-975.
  57. The future of hypertension therapy: sense, antisense, or nonsense? / [Pachori A. S., Huentelman M. J., Francis S.C. et al.] // Hypertension.- 2001.- V. 37.- P. 357-364.
  58. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA / [Wang H., Katovich M. J., Gelband C. H. et al.] // Circ Res.- 1999.- V. 85.- P. 614-622.
  59. Akhmeteli M. A. Epidemiologicheskiye issledovaniya serdechno-sosudistykh zabolevaniy i ikh profilaktika / Akhmeteli M. A. // Sov. zdravookh.- 1982.- No 5.- S. 20-23.
  60. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense / Kimura B., Mohuczy D., Tang X., Phillips M. I. // Hypertension.- 2001.- V. 37.- P. 376-380.
  61. Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats /Zhang Y. C., Bui J. D., Shen L., Phillips M. I // Circulation.- 2000.- V. 101.- P. 682-688.
  62. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense / [Kagiyama S., Eguchi S., Frank G.D. et al.] // Circulation.- 2002.- V. 106.- P 909-912.
  63. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy / Kagiyama S., Qian K., Kagiyama T., Phillips M. I. // Hypertension.- 2003.- V. 41.- P 824-829.
  64. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats / Dobrzynski E., Wang C., Chao J., Chao L. // Hypertension.- 2000.- V. 36.- P 995-1001.
  65. Lin K. F. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats / Lin K. F., Chao J., Chao L. // Hypertension.- 1995.- V. 26.- P 847-853.
  66. Wang C. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats / Wang C., Chao L., Chao J. // J Clin Invest.- 1995.- V. 95.- P 1710-1716.
  67. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats / [Zhang J. J., Wang C., Lin K. F. et al.] // Clin Exp Hypertens.- 1999.- V. 21.- P 1145-1160.
  68. Babayan E. A. Gigiyenicheskaya reglamentatsiya khimicheskikh veshchestv v okruzhayushchey srede s uchetom ikh deystviya na SSS / E. A. Babayan // V kn.: Mat. nauchn. konf. po rezul'tatam NIR mezhvedomstvenn. Programmy MZ i AN ArmSSR Yerevan, 1985.- S. 14.
  69. 69. Babayan E. A. Nekotoryye metodicheskiye voprosy gigiyenicheskogo normirovaniya kardiotoksicheskikh veshchestv v vozdukhe rabochey zony / E. A. Babayan // V kn.: Probl. okhrany zdorov'ya naseleniya i zashchity okruzhayushchey sredy ot khimicheskikh vrednykh faktorov: Tez.dokl. I Vsesoyuzn. s"yezda toksikologov.- Rostov-na-Donu, 1986.- S. 48-49.
  70. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer / [Metcalfe B. L., Huentelman M. J., Parilak L. D. et al.] // Hypertension.- 2004.- V. 43.- P. 1233-1238.
  71. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril- insensitive carboxypeptidase / [Tipnis S. R., Hooper N. M., Hyde R. et al.] // J Biol Chem.- 2000.- V. 275.- P. 33238-33243.
  72. Turner A. J. The angiotensin-converting enzyme gene family: genomics and pharmacology / A. J. Turner, N. M. Hooper // Trends Pharmacol Sci.- 2002.- V. 23.- P. 177-183.
  73. Angiotensin-converting enzyme 2 is an essential regulator of heart function / [Crackower M. A., Sarao R., Oudit G. Y. et al.] // Nature.- 2002.- V. 417.- P. 822-828.
  74. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system / [Roks A. J., van Geel P. P, Pinto Y. M. et al.] // Hypertension.- 1999.- V. 34.- P. 296-301.
  75. Angiotensin-( 1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man / [Ueda S., Masumori-Maemoto S., Ashino K. et al.] // Hypertension.- 2000.- V. 35.- P. 998-1001.
  76. Protection from angiotensin Il-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 / [Huentelman M. J., Grobe J. L., Vazquez J. et al.] // Exp Physiol.- 2005.- V. 90.- P. 783-790.
  77. Cloning and characterization of a secreted form of angiotensin-converting enzyme 2 / Huentelman M. J., Zubcevic J., Katovich M. J., Raizada M. K. // Regul Pept.- 2004.- V. 122.- P 61-67.
  78. Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system / [Tang Y. L., Tang Y., Zhang Y. C. et al.] // Hypertension.- 2004.- V. 43.- P 746-751.